Search

Your search keyword '"Royal North Shore Hospital (RNSH)"' showing total 20 results
Start Over Author "Royal North Shore Hospital (RNSH)" Database OpenAIRE
20 results on '"Royal North Shore Hospital (RNSH)"'

1. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study

Author

Sandra Nolte, Laura L Laslett, Anthony D. Woolf, Emma Smith, Theo Vos, Damian G Hoy, Ilana N. Ackerman, Marita Cross, Richard H. Osborne, Marlene Fransen, Flavia M. Cicuttini, Lisa Bridgett, Rachelle Buchbinder, Graeme Jones, Lyn March, Sean R.M. Williams, Francis Guillemin, Christopher Hill, Institute of Bone & Joint Research, Royal North Shore Hospital (RNSH)-The University of Sydney, School of Population Health, University of Queensland, Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin, Institute of Public Health [Berlin, Germany], School of Health and Social Development [Deakin University], Deakin University [Burwood], The Royal Melbourne Hospital, Melbourne EpiCentre, Faculty of Health Sciences [University of Sydney], The University of Sydney, School of Medicine [Western Sydney University], Western Sydney University (UWS), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), The Queen Elizabeth Hospital, Adelaide, The Health Observatory [University of Adelaide], University of Adelaide, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia, University of Tasmania (UTAS), Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia, Monash University [Clayton], Institute for Health Metrics and Evaluation [University of Washington], University of Washington [Seattle], Cabrini Institute, Monash University [Melbourne], Royal Cornwall Hospital, Royal North Shore Hospital ( RNSH ) -The University of Sydney [Sydney], Charite-Universitatsmedizin Berlin [Berlin], Hôpital universitaire de la Charité de Berlin, Melbourne Medical School-The Royal Melbourne Hospital, The University of Sydney [Sydney], Western Sydney University ( UWS ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université de Lorraine ( UL ) -Université Paris Descartes - Paris 5 ( UPD5 ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Western Sydney University, and University of Tasmania [Hobart, Australia] (UTAS)

Subjects
Male, MESH : Prevalence, Epidemiology, MESH : Age Distribution, MESH : Aged, MESH: Global Health, Osteoarthritis, MESH : Child, Preschool, Global Health, MESH: Regression Analysis, Severity of Illness Index, Osteoarthritis, Hip, MESH: Aged, 80 and over, MESH : Child, Cost of Illness, MESH : Regression Analysis, MESH: Child, MESH: Osteoarthritis, Knee, Prevalence, Immunology and Allergy, MESH : Cost of Illness, MESH : Female, MESH: Incidence, Young adult, Child, MESH : Sex Distribution, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Incidence, Incidence (epidemiology), MESH: Sex Distribution, MESH : Infant, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Adult, MESH: Cost of Illness, Middle Aged, Osteoarthritis, Knee, MESH: Infant, MESH : Incidence, 3. Good health, MESH: Quality-Adjusted Life Years, MESH: Young Adult, Child, Preschool, Regression Analysis, MESH : Severity of Illness Index, Female, Quality-Adjusted Life Years, MESH : Osteoarthritis, Hip, Adult, musculoskeletal diseases, medicine.medical_specialty, Adolescent, MESH : Male, Immunology, Population, MESH : Young Adult, General Biochemistry, Genetics and Molecular Biology, Knee Osteoarthritis, Young Adult, Age Distribution, Rheumatology, MESH : Adolescent, MESH: Severity of Illness Index, Severity of illness, medicine, Humans, MESH : Middle Aged, MESH : Osteoarthritis, Knee, Sex Distribution, MESH : Aged, 80 and over, education, MESH: Age Distribution, MESH: Prevalence, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH: Child, Preschool, Infant, MESH: Adult, MESH : Quality-Adjusted Life Years, medicine.disease, Obesity, MESH: Male, Quality-adjusted life year, Physical therapy, MESH : Global Health, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Osteoarthritis, Hip, business, MESH: Female
Abstract

International audience; OBJECTIVE:To estimate the global burden of hip and knee osteoarthritis (OA) as part of the Global Burden of Disease 2010 study and to explore how the burden of hip and knee OA compares with other conditions.METHODS:Systematic reviews were conducted to source age-specific and sex-specific epidemiological data for hip and knee OA prevalence, incidence and mortality risk. The prevalence and incidence of symptomatic, radiographic and self-reported hip or knee OA were included. Three levels of severity were defined to derive disability weights (DWs) and severity distribution (proportion with mild, moderate and severe OA). The prevalence by country and region was multiplied by the severity distribution and the appropriate disability weight to calculate years of life lived with disability (YLDs). As there are no deaths directly attributed to OA, YLDs equate disability-adjusted life years (DALYs).RESULTS:Globally, of the 291 conditions, hip and knee OA was ranked as the 11th highest contributor to global disability and 38th highest in DALYs. The global age-standardised prevalence of knee OA was 3.8% (95% uncertainty interval (UI) 3.6% to 4.1%) and hip OA was 0.85% (95% UI 0.74% to 1.02%), with no discernible change from 1990 to 2010. Prevalence was higher in females than males. YLDs for hip and knee OA increased from 10.5 million in 1990 (0.42% of total DALYs) to 17.1 million in 2010 (0.69% of total DALYs).CONCLUSIONS:Hip and knee OA is one of the leading causes of global disability. Methodological issues within this study make it highly likely that the real burden of OA has been underestimated. With the aging and increasing obesity of the world's population, health professions need to prepare for a large increase in the demand for health services to treat hip and knee OA.

Published
2014

2. Effective orifice area assessment in BI-leaflet mechanical valves by MRI

Author

EVIN, Morgan, Lalande, A., Joannic, David, Fontaine, J.-F., Wang, Yufei, Fletcher, D. F., Callaghan, D.F., Grieve, SM, The University of Sydney [Sydney], Laboratoire Electronique, Informatique et Image ( Le2i ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), School of Chemical and Biomolecular Engineering, Royal North Shore Hospital ( RNSH ), The University of Sydney, Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Royal North Shore Hospital (RNSH), Fontaine, Jean François, Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Arts et Métiers (ENSAM), and HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement

Subjects
[ SPI.MECA.GEME ] Engineering Sciences [physics]/Mechanics [physics.med-ph]/Mechanical engineering [physics.class-ph], [SPI.MECA.GEME] Engineering Sciences [physics]/Mechanics [physics.med-ph]/Mechanical engineering [physics.class-ph], [SPI.MECA.GEME]Engineering Sciences [physics]/Mechanics [physics.med-ph]/Mechanical engineering [physics.class-ph]
Abstract

International audience; Effective orifice area (EOA) and mean pressure gradientare routine echocardiographic measurements of valvularprosthesis function in both the mitral and aortic position.EOA computation is based on the continuity equationand is used to describe the “effective” orifice formed bythe flow traversing a geometrical orifice. In the case ofbi-leaflet biomechanical valvular prosthesis (BMHV),the orifice of the valve is divided into 3 zones. BMHVperformance assessment by MRI have been described inthe in-vitro setting in [1] using the maximum pressuregradient. Additionally, a method using jet layer has beenused to detect EOA dynamically [2]. 4D-PC flowsequences enable measurement of three velocitycomponents by MRI with a temporal resolutionaveraging (~ 30 msec). In patients with a BMHV,despite the metallic blurring due to the valve structure,MRI examination enhances both anatomical andhemodynamic diagnosis. Aim of this work is to assessthe capacity of MRI to measure BMHV EOA by 4D-PCflowMRI, using simple computational fluid dynamic(CFD) simulation for validation.

Published
2016

3. Utility of (18)fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma

Author

Lauren Pinter-Brown, Steven M. Horwitz, John Balser, Bertrand Coiffier, Andrei R. Shustov, Jean Nichols, Barbara Balser, Matthew Greenwood, F. Morschhauser, Henry Miles Prince, Lubomir Sokol, Francine M. Foss, Swaminathan P. Iyer, Dolores Caballero, Barbara Pro, Memorial Sloan Kettering Cancer Center (MSKCC), Hospices Civils de Lyon (HCL), Yale Cancer Center, Yale University School of Medicine, Peter Mac Callum Cancer Centre, H. Lee Moffitt Cancer Center and Research Institute, Royal North Shore Hospital (RNSH), Universidad de Salamanca, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Harbor UCLA Medical Center [Torrance, Ca.], Houston Methodist Hospital [Houston, TX, USA], University of Washington [Seattle], University of Liverpool, Jefferson University Hospitals, Université de Lille, CHU Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - EA 7365, Memorial Sloan Kettering Cancer Center [MSKCC], Hospices Civils de Lyon, Departement de Neurologie [HCL], Royal North Shore Hospital [RNSH], Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA], Yale School of Medicine [New Haven, Connecticut] (YSM), and Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

Subjects
0303 health sciences, medicine.diagnostic_test, business.industry, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Phases of clinical research, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, 3. Good health, Romidepsin, 03 medical and health sciences, 0302 clinical medicine, Oncology, Refractory, Positron emission tomography, 030220 oncology & carcinogenesis, medicine, Clinical endpoint, Radiation treatment planning, Nuclear medicine, business, Prospective cohort study, Survival rate, 030304 developmental biology, medicine.drug
Abstract

International audience; BACKGROUND: For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis and response to treatment remains unclear. The utility of FDG-PET, in addition to conventional radiology, was examined as a planned exploratory end point in the pivotal phase 2 trial of romidepsin for the treatment of relapsed/refractory PTCL.PATIENTS AND METHODS: Patients received romidepsin at a dose of 14 mg/m(2) on days 1, 8, and 15 of 28-day cycles. The primary end point was the rate of confirmed/unconfirmed complete response (CR/CRu) as assessed by International Workshop Criteria (IWC) using conventional radiology. For the exploratory PET end point, patients with at least baseline FDG-PET scans were assessed by IWC + PET criteria.RESULTS: Of 130 patients, 110 had baseline FDG-PET scans, and 105 were PET positive at baseline. The use of IWC + PET criteria increased the objective response rate to 30% compared with 26% by conventional radiology. Durations of response were well differentiated by both conventional radiology response criteria [CR/CRu versus partial response (PR), P = 0.0001] and PET status (negative versus positive, P < 0.0001). Patients who achieved CR/CRu had prolonged progression-free survival (PFS, median 25.9 months) compared with other response groups (P = 0.0007). Patients who achieved PR or stable disease (SD) had similar PFS (median 7.2 and 6.3 months, respectively, P = 0.6427). When grouping PR and SD patients by PET status, patients with PET-negative versus PET-positive disease had a median PFS of 18.2 versus 7.1 months (P = 0.0923).CONCLUSIONS: Routine use of FDG-PET does not obviate conventional staging, but may aid in determining prognosis and refine response assessments for patients with PTCL, particularly for those who do not achieve CR/CRu by conventional staging. The optimal way to incorporate FDG-PET scans for patients with PTCL remains to be determined.TRIAL REGISTRATION: NCT00426764.

Published
2015

4. Updating the OMERACT Filter: Implications for Patient-reported Outcomes

Author

M. Voshaar, Anne Lyddiatt, Wilma Smeets, Amye L. Leong, James W. May, T.K. Kvien, Pamela Montie, Maarten Boers, John R. Kirwan, Dorcas E. Beaton, Peter Tugwell, Susan J. Bartlett, Lyn March, Vibeke Strand, Ernest Choy, Ailsa Bosworth, Laure Gossec, Sarah Hewlett, Pam Richards, Peter Brooks, Francis Guillemin, Maarten de Wit, Robert Landewé, Enkeleida Nikaï, Institute for Work and Health (IWH), University of Toronto-St. Michael's Hospital-Institute of Medical Sciences, Department of Clinical Epidemiology and Biostatistics, VU University Medical Center [Amsterdam], National Rheumatoid Arthritis Society (NRAS), Institut Jacques Monod (IJM (UMR_7592)), Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), EULAR standing committee of People with Arthritis/Rheumatism in Europe (PARE), Ecole de Santé Publique [Nancy], Faculté de Médecine [Nancy], Université de Lorraine (UL)-Université de Lorraine (UL), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Université Sorbonne Paris Cité (USPC), Dpt of Clinical Immunology & Rheumatology [Amsterdam], Amsterdam and Atrium Medical Center, Institute of Bone & Joint Research, Royal North Shore Hospital (RNSH)-The University of Sydney, Stanford School of Medicine [Stanford], Stanford Medicine, Stanford University-Stanford University, University of Ottawa [Ottawa], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Stanford University School of Medicine [Stanford], Stanford University [Stanford], University of Ottawa [Ottawa] (uOttawa), CHU Cochin [AP-HP], Institute for Work and Health ( IWH ), University Medical Center, National Rheumatoid Arthritis Society ( NRAS ), Institut Jacques Monod ( IJM ), Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Université de Lorraine ( UL ) -Université de Lorraine ( UL ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université de Lorraine ( UL ) -Université Paris Descartes - Paris 5 ( UPD5 ), Université Sorbonne Paris Cité ( USPC ), Royal North Shore Hospital ( RNSH ) -The University of Sydney [Sydney], Amsterdam institute for Infection and Immunity, Clinical Immunology and Rheumatology, Epidemiology and Data Science, Rheumatology, and CCA - Innovative therapy

Subjects
medicine.medical_specialty, MESH: Self Report, International studies, Immunology, Alternative medicine, MESH : Rheumatic Diseases, MESH : Self Report, MESH : Randomized Controlled Trials as Topic, Outcome (game theory), Filter (software), Session (web analytics), MESH: Patient Participation, law.invention, MESH: Rheumatic Diseases, Randomized controlled trial, Rheumatology, law, Rheumatic Diseases, MESH: Rheumatology, MESH : Outcome and Process Assessment (Health Care), Immunology and Allergy, Medicine, Humans, Good practice, MESH : Rheumatology, OUTCOME AND PROCESS ASSESSMENT, Randomized Controlled Trials as Topic, RANDOMIZED CONTROLLED TRIALS, Medical education, MESH: Humans, business.industry, MESH : Reproducibility of Results, MESH : Humans, Reproducibility of Results, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Patient Participation, MESH: Reproducibility of Results, Outcome and Process Assessment, Health Care, MESH: Randomized Controlled Trials as Topic, PATIENT-REPORTED OUTCOMES, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Self Report, Patient Participation, business, Working group, MESH: Outcome and Process Assessment (Health Care)
Abstract

Objective.At a previous Outcome Measures in Rheumatology (OMERACT) meeting, participants reflected on the underlying methods of patient-reported outcome (PRO) instrument development. The participants requested proposals for more explicit instrument development protocols that would contribute to an enhanced version of the “Truth” statement in the OMERACT Filter, a widely used guide for outcome validation. In the present OMERACT session, we explored to what extent these new Filter 2.0 proposals were practicable, feasible, and already being applied.Methods.Following overview presentations, discussion groups critically reviewed the extent to which case studies of current OMERACT Working Groups complied with or negated the proposed PRO development framework, whether these observations had a more general application, and what issues remained to be resolved.Results.Several aspects of PRO development were recognized as particularly important, and the need to directly involve patients at every stage of an iterative PRO development program was endorsed. This included recognition that patients contribute as partners in the research and not merely as subjects. Correct communication of concepts with the words used in questionnaires was central to their performance as measuring instruments, and ensuring this understanding crossed cultural and linguistic boundaries was important in international studies or comparisons.Conclusion.Participants recognized, endorsed, and were generally already putting into practice the principles of PRO development presented in the plenary session. Further work is needed on some existing instruments and on establishing widespread good practice for working in close collaboration with patients.

Published
2014

5. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

Author

Camilo Jimenez, Henricus P. M. Kunst, Eric Baudin, Nicola Tufton, Philippe Herman, Rodney J. Hicks, Simon Aylwin, Mercedes Robledo, Henri J L M Timmers, Anne Paule Gimenez-Roqueplo, William F. Young, Massimo Mannelli, Roderick J. Clifton-Bligh, Patricia L. M. Dahia, Mitsuhide Naruse, Alexandre Buffet, Andrzej Januszewicz, Olivier Steichen, Scott Akker, Charlotte Lussey-Lepoutre, Karel Pacak, Martin Fassnacht, David R Taylor, Laurence Amar, Ashley B. Grossman, Giorgio Treglia, Jacques W.M. Lenders, Dylan Lewis, Nelly Burnichon, David Taïeb, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Service de Médecine Interne [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), St Bartholomew's Hospital, King's College Hospital (KCH), Institut Gustave Roussy (IGR), Médecine nucléaire, Département d'imagerie médicale [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Royal North Shore Hospital (RNSH), The University of Sydney, The University of Texas at San Antonio (UTSA), University of Würzburg, Churchill Hospital, Churchill Hospital Oxford Centre for Haematology, Royal Free Hospital [London, UK], Barts & The London School of Medicine and Dentistry, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Melbourne, Institute of Cardiology (WARSAW - Cardiology), Institute of Cardiology, The University of Texas M.D. Anderson Cancer Center [Houston], Radboud University Medical Center [Nijmegen], Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Kyoto Medical Center, National Hospital Organization, Spanish National Cancer Research Center (CNIO), Centro de Investigación Biomédica en Red de Enfermedades Raras - CIBERER [Santiago de Compostela, Spain] (Grupo de Medicina Xenómica), Universidade de Santiago de Compostela [Spain] (USC ), Hôpital de la Timone [CHU - APHM] (TIMONE), Ente Ospedaliero Cantonale (EOC), Lausanne University Hospital, Università della Svizzera italiana = University of Italian Switzerland (USI), Mayo Clinic, Technische Universität Dresden = Dresden University of Technology (TU Dresden), Service de médecine nucléaire [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, KNO, and MUMC+: MA Keel Neus Oorheelkunde (9)

Subjects
0301 basic medicine, PHEOCHROMOCYTOMA, Pediatrics, Internationality, SDHB, Endocrinology, Diabetes and Metabolism, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], 0302 clinical medicine, Endocrinology, Mass Screening, CAROTID-BODY TUMORS, Child, HIGH-ALTITUDE, Molecular medicine, medicine.diagnostic_test, Genetic Carrier Screening, GASTROINTESTINAL STROMAL TUMORS, Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16], [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Penetrance, 3. Good health, Succinate Dehydrogenase, PARAGANGLIOMA, 030220 oncology & carcinogenesis, Mutation (genetic algorithm), Algorithms, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Adult, Heterozygote, PENETRANCE, medicine.medical_specialty, Consensus, Genetic counseling, Adrenal tumours, 03 medical and health sciences, Germline mutation, medicine, Humans, Genetic Testing, Germ-Line Mutation, Mass screening, Aged, Monitoring, Physiologic, Genetic testing, business.industry, CLINICAL UTILITY, GENE, METANEPHRINES, 030104 developmental biology, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Asymptomatic Diseases, MATERNAL TRANSMISSION, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, SDHD, business
Abstract

Approximately 20% of patients diagnosed with a phaeochromocytoma or paraganglioma carry a germline mutation in one of the succinate dehydrogenase (SDHx) genes (SDHA, SDHB, SDHC and SDHD), which encode the four subunits of the SDH enzyme. When a pathogenic SDHx mutation is identified in an affected patient, genetic counselling is proposed for first-degree relatives. Optimal initial evaluation and follow-up of people who are asymptomatic but might carry SDHx mutations have not yet been agreed. Thus, we established an international consensus algorithm of clinical, biochemical and imaging screening at diagnosis and during surveillance for both adults and children. An international panel of 29 experts from 12 countries was assembled, and the Delphi method was used to reach a consensus on 41 statements. This Consensus Statement covers a range of topics, including age of first genetic testing, appropriate biochemical and imaging tests for initial tumour screening and follow-up, screening for rare SDHx-related tumours and management of elderly people who have an SDHx mutation. This Consensus Statement focuses on the management of asymptomatic SDHx mutation carriers and provides clinicians with much-needed guidance. The standardization of practice will enable prospective studies in the near future.

Published
2021

6. The identification, assessment and management of difficult-to-treat depression: An international consensus statement

Author

Allan H. Young, Gin S Malhi, RH McAllister-Williams, Eduard Vieta, Philip Gorwood, Afzal Javed, Peter Falkai, Andrew Papadopoulos, A. J. Rush, Celso Arango, Jair C. Soares, Malcolm Hopwood, Pierre Blier, Koen Demyttenaere, Siegfried Kasper, Martinez Rico, Clara, Newcastle University [Newcastle], Newcastle Upon Tyne Hospitals NHS Foundation Trust, Instituto de Investigación Sanitaria Gregorio Marañón [Madrid, Spain] ( IiSGM), Centro de Investigación Biomédica en Red Salud Mental [Madrid] (CIBER-SAM), University of Ottawa [Ottawa], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Ludwig Maximilian University [Munich] (LMU), Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Melbourne, University of Warwick [Coventry], Medizinische Universität Wien = Medical University of Vienna, The University of Sydney, Royal North Shore Hospital (RNSH), The University of Texas Health Science Center at Houston (UTHealth), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), King‘s College London, South London and Maudsley NHS Foundation Trust, Somerset Partnership NHS Foundation Trust, Duke University [Durham], Texas Tech University Health Sciences Center, Texas Tech University [Lubbock] (TTU), Duke-NUS Medical School [Singapore], and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)

Subjects
VAGUS NERVE-STIMULATION, TRANSCRANIAL MAGNETIC STIMULATION, medicine.medical_specialty, Consensus, 2016 CLINICAL GUIDELINES, SEROTONIN REUPTAKE INHIBITORS, medicine.medical_treatment, Clinical Neurology, GENERALIZED ANXIETY DISORDER, Difficult-to-treat depression, Depressive Disorder, Treatment-Resistant, DOUBLE-BLIND, 03 medical and health sciences, POSTTRAUMATIC-STRESS-DISORDER, 0302 clinical medicine, Pharmacotherapy, Diagnosis, medicine, Humans, Symptom control, COGNITIVE-BEHAVIORAL THERAPY, Intensive care medicine, Neurostimulation, Psychiatry, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Science & Technology, Conceptualization, Depression, Clinical management, business.industry, Treatment options, MAJOR DEPRESSION, medicine.disease, 3. Good health, 030227 psychiatry, Psychotherapy, Psychiatry and Mental health, Clinical Psychology, Management implications, Quality of Life, TREATMENT-RESISTANT DEPRESSION, Neurosciences & Neurology, Treatment-resistant depression, business, Life Sciences & Biomedicine, Psychosocial, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030217 neurology & neurosurgery
Abstract

BACKGROUND: Many depressed patients are not able to achieve or sustain symptom remission despite serial treatment trials - often termed "treatment resistant depression". A broader, perhaps more empathic concept of "difficult-to-treat depression" (DTD) was considered. METHODS: A consensus group discussed the definition, clinical recognition, assessment and management implications of the DTD heuristic. RESULTS: The group proposed that DTD be defined as "depression that continues to cause significant burden despite usual treatment efforts". All depression management should include a thorough initial assessment. When DTD is recognized, a regular reassessment that employs a multi-dimensional framework to identify addressable barriers to successful treatment (including patient-, illness- and treatment-related factors) is advised, along with specific recommendations for addressing these factors. The emphasis of treatment, in the first instance, shifts from a goal of remission to optimal symptom control, daily psychosocial functional and quality of life, based on a patient-centred approach with shared decision-making to enhance the timely consideration of all treatment options (including pharmacotherapy, psychotherapy, neurostimulation, etc.) to optimize outcomes when sustained remission is elusive. LIMITATIONS: The recommended definition and management of DTD is based largely on expert consensus. While DTD would seem to have clinical utility, its specificity and objectivity may be insufficient to define clinical populations for regulatory trial purposes, though DTD could define populations for service provision or phase 4 trials. CONCLUSIONS: DTD provides a clinically useful conceptualization that implies a search for and remediation of specific patient-, illness- and treatment obstacles to optimizing outcomes of relevance to patients. ispartof: Journal of Affective Disorders vol:267 pages:264-282 ispartof: location:Netherlands status: published

Published
2020

7. GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis

Author

Juliana Perez Botero, Keith Gomez, Maha Othman, Willem H. Ouwehand, Kate Downes, Kathleen Freson, Marie-Christine Morel-Kopp, David-Alexandre Trégouët, Neil V. Morgan, José María Bastida, Shannon Brooks, Harald Schulze, Loredana Bury, José Rivera, Eva Leinoe, Karyn Megy, University of Cambridge [UK] (CAM), Cambridge University Hospitals - NHS (CUH), Royal North Shore Hospital (RNSH), The University of Sydney, Instituto de Investigación Biomédica de Salamanca [Salamanca, Spain] (IBSAL/CIC), Università degli Studi di Perugia (UNIPG), National University Hospital, Rigshospitalet, Copenhagen, Royal Free London NHS Foundation Trust, University of Birmingham [Birmingham], Queen's University [Kingston, Canada], Medical College of Wisconsin [Milwaukee] (MCW), Universidad de Murcia, University Hospital Wuerzburg, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven)

Subjects
Platelets, Platelet disorder, Hemorrhage, Genomics, Computational biology, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Resource (project management), blood, MANAGEMENT, Humans, Medicine, genes, thrombosis, 030304 developmental biology, Hemostasis, 0303 health sciences, Science & Technology, business.industry, Communication, Genetic variants, Thrombosis, Hematology, Pathogenicity, medicine.disease, 3. Good health, Blood, Genes, Peripheral Vascular Disease, Mutation, platelets, Cardiovascular System & Cardiology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Blood Platelet Disorders, hemorrhage, mutation, business, Life Sciences & Biomedicine
Abstract

The implementation of high-throughput sequencing (HTS) technologies in research and diagnostic laboratories has linked many new genes to rare bleeding, thrombotic, and platelet disorders (BTPD), and revealed multiple genetic variants linked to those disorders, many of them being of uncertain pathogenicity when considering the accepted evidence (variant consequence, frequency in control datasets, number of reported patients, prediction models, and functional assays). The sequencing effort has also resulted in resources for gathering disease-causing variants associated with specific genes, but for BTPD, such well-curated databases exist only for a few genes. On the other hand, submissions by individuals or diagnostic laboratories to the variant database ClinVar are hampered by the lack of a submission process tailored to capture the specific features of hemostatic diseases. As we move toward the implementation of HTS in the diagnosis of BTPD, the Scientific and Standardization Committee for Genetics in Thrombosis and Haemostasis has developed and tested a REDCap-based interface, aimed at the community, to submit curated genetic variants for diagnostic-grade BTPD genes. Here, we describe the use of the interface and the initial submission of 821 variants from 30 different centers covering 14 countries. This open-access variant resource will be shared with the community to improve variant classification and regular bulk data transfer to ClinVar. ispartof: JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol:19 issue:10 pages:2612-2617 ispartof: location:England status: published

Published
2021

8. Decline in subarachnoid haemorrhage volumes associated with the first wave of the COVID-19 pandemic

Author

Ajit S. Puri, Allan Taylor, Huynh Le Vu, Tatemi Todaka, Teddy Y. Wu, Octavio M. Pontes-Neto, Eytan Raz, Pedro Lylyk, Jasmine Johann, Roberta Novakovic, Hormuzdiyar H. Dasenbrock, Francisco Mont’Alverne, Nobuyuki Sakai, Melanie Walker, Hugh Stephen Winters, Ossama Mansour, Yohei Takenobu, Gregory Walker, Miki Fujimura, Saif Bushnaq, Odysseas Kargiotis, Nabeel Herial, Markus A Möhlenbruch, Malveeka Sharma, Hiroshi Tokimura, Maxim Mokin, Jean Raymond, Michael D. Hill, Amal Abou-Hamden, Leonardo Renieri, Serdar Geyik, Yuri Sugiura, Luisa Fonseca, Roberto Crosa, Fabricio O Lima, Ameer E Hassan, Viet Quy Nguyen, Jane G. Morris, Steven W. Hetts, Jawad F. Kirmani, Matthew S. Tenser, Muhammad M. Qureshi, Gianmarco Bernava, Mahmoud H Mohammaden, Verónica V. Olavarría, Jun Deguchi, André Beer-Furlan, Steve M. Cordina, Hiroshi Yamagami, Mohamad Abdalkader, Toshiyuki Fujinaka, Clifford J. Eskey, Rotem Sivan-Hoffmann, Hao Zhang, Anirudh Kulkarni, Brendan Steinfort, Özlem Aykaç, Barbara Voetsch, Alex Brehm, Italo Linfante, Wenguo Huang, Omer Eker, M. Luis Silva, Pascal Jabbour, Lissa Peeling, Mollie McDermott, Pascale Lavoie, Kazutaka Sonoda, Thomas Devlin, Alicia C. Castonguay, Jin Soo Lee, Diogo C Haussen, Dileep R. Yavagal, Thanh N. Nguyen, Umair Rashid, Vasu Saini, Raghid Kikano, Hiroyuki Hashimoto, Masaaki Uno, Saima Ahmad, Artem Kaliaev, Eiji Hagashi, Ajay K. Wakhloo, Romain Bourcier, Ryoo Yamamoto, Jesse M. Thon, Georgios Tsivgoulis, Dorothea Altschul, Achmad Fidaus Sani, Satoshi Yamada, Varsha Singh, David S Liebeskind, Tatsuo Amano, Anchalee Churojana, Juan F. Arenillas, Junichi Iida, Charles C. Matouk, Nobuyuki Ohara, Osama O. Zaidat, Mario Martínez-Galdámez, Chandril Chugh, Don Frei, Vanessa Chalumeau, Brijesh P Mehta, Marios Psychogios, Anna Luisa Kühn, Leticia C Rebello, Xianjin Shang, Hosam Al-Jehani, Hiroki Fukuda, Hong Gee Roh, Gisele Sampaio Silva, Rakesh Khatri, Kenichi Todo, Amal Al Hashmi, Alex Bou Chebl, Sunil A Sheth, Zhongming Qiu, Oriana Cornett, Zhengzhou Yuan, Wazim Izzath, Hesham Masoud, Rodrigo Rivera, Michel Piotin, Vikram Huded, Mamoru Murakami, Mohamed Teleb, Viktor Szeder, Ruchir Shah, Dheeraj Gandhi, John Thornton, Michael Chen, Vitor Mendes Pereira, Nadia Hammami, Alice Ma, Anna M. Cervantes-Arslanian, James E. Siegler, Seby John, Carlos Ynigo Lopez, Mudassir Farooqui, David Ozretić, Takuya Kanamaru, Romain Guile, Daisuke Watanabe, Kosuke Miyake, Alejandro Rodriguez Vasquez, Patrick Nicholson, Yuki Yamamoto, William J. Mack, Naoto Kimura, Simon Mathew John, Robert Fahed, Yuji Matsumaru, David Y. Chung, Rishi Gupta, Ryuhei Kono, Michael Frankel, Victor S. Lopez Rivera, Johanna T. Fifi, Raul G Nogueira, Paolo Machi, Tudor G. Jovin, Jordi Blasco, Emma Griffin, Salvatore Mangiafico, Masafumi Morimoto, Jun Luo, Santiago Ortega-Gutierrez, Monika Killer-Oberpfalzer, Daniel Giansante Abud, Syed I. Hussain, Fawaz Al-Mufti, Yusuke Sugimura, Atilla Özcan Özdemir, Stephan A. Mayer, Sumeet Multani, Adel Alhazzani, Alhamza R Al-Bayati, Michael Kelly, Lee A Birnbaum, Shadi Yaghi, Jeyaraj D Pandian, Ji Man Hong, Junsuke Shimbo, Johnny Ho-Yin Wong, Elena A. Cora, Laura Mechtouff, Pedro S.C. Magalhães, Pablo M. Lavados, Yuichi Murayama, Dong Hun Shin, Simon Nagel, Ken Wong, Jose Antonio Fiorot, Jeremy Payne, Randall C. Edgell, Adrienne Weeks, CarMeN, laboratoire, Department of Neurology [Boston], Harvard Medical School [Boston] (HMS)-Massachusetts General Hospital [Boston], Emory University School of Medicine, Emory University [Atlanta, GA], Boston University School of Medicine (BUSM), Boston University [Boston] (BU), National Hospital Organization Osaka National Hospital [Japon] (NHO Osaka National Hospital), Alexandria University [Alexandrie], Boston Medical Center [Boston, MA, USA] (BMC), Xinqiao Hospital [Chongqing, China] (XH), University of Cape Town, La Sagrada Familia Clinic/Clínica La Sagrada Familia [Buenos Aires, Argentina] (LSFC), Hospices Civils de Lyon (HCL), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Hospital General de Fortaleza [Fortaleza, Brazil] (HGF), Nottingham University Hospitals NHS Trust [UK], Kobe City Medical Center General Hospital [Kobe, Hyogo, Japan] (KCMCGH), Azienda Ospedaliero-Universitaria Careggi [Firenze, Toscana, Italy] (AOUC), University Hospital Centre Zagreb, Partenaires INRAE, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service de Neuroradiologie [CHU de Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cleveland Clinic Abu Dhabi [Abou Dabi, Émirats arabes unis], Hôpital de Beaumont [Dublin, Ireland] (HB), Hospital-Estadual Central [Vitoria, Brazil] (HEC), Instituto de NeuroCirugía Asenjo, Institut national de neurologie Mongi-Ben Hamida [Tunis], Hue Central Hospital [Thua Thien Hue, Vietnam] (HCH), University of California [San Francisco] (UC San Francisco), University of California (UC), Centre hospitalier universitaire de Nantes (CHU Nantes), Washington University School of Medicine (WUSM), University of Washington [Seattle], Englewood Hospital and Medical Center [Englewood], Jefferson (Philadelphia University + Thomas Jefferson University), Westchester Medical Center [Valhalla, New York, USA] (WMC), Eskisehir Osmangazi University, University of Maryland School of Medicine, University of Maryland System, MAX Superspecialty Hospital [Saket, New Delhi, India] (MSH), Yale School of Medicine [New Haven, Connecticut] (YSM), Université Laval [Québec] (ULaval), Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), Rush University Medical Center [Chicago], Paracelsus Medizinische Privatuniversität = Paracelsus Medical University (PMU), University of Toronto, NH Mazumdar Shah Medical Center [Bangalore, India] (NHMSMC), IMS Tokyo-Katsushika General Hospital [Tokyo, Japan], Gachon University [Seongnam, Korea] (GU), Hospital Municipal Sao Jose [Joinville, Santa Catarina, Brazil] (HMSJ), Lau Medical Center [Beirut, Lebanon] (LMC), University of Iowa [Iowa City], Royal Adelaide Hospital [Adelaide Australia], Kyorin University [Tokyo, Japan], Yokohama Brain and Spine Center [Yokohama, Japan] (YBSC), Dalhousie University [Halifax], Rambam Health Care Campus [Haifa, Israel], Centro Endovascular Neurologico Medica Uruguaya [Montevideo, Uruguay] (CENMU), Heidelberg University Hospital [Heidelberg], Imam Abdulrahman bin Faisal University [Alkhobar, Saudi Arabia] (IAFU), McGovern Medical School [Houston, TX, USA] (McGMS), The University of Texas Health Science Center at Houston (UTHealth), Cooper Medical School of Rowan University [Camden] (CMSRU), Airlangga University [Jawa Timur, Indonesia] (AU), University of Massachusetts Medical School [Worcester] (UMASS), University of Massachusetts System (UMASS), Geneva University Hospitals and Geneva University, Universidade de São Paulo = University of São Paulo (USP), Beth Israel Lahey Health [Burlington, MA, USA] (BILH), New York University School of Medicine (NYU Grossman School of Medicine), Memorial Neuroscience Institute [Pembroke Pines, FL, USA] (MNI), Iwate Prefectural Central Hospital [Morioka, Iwate, Japan] (IPCH), Japanese Red Cross Musashino Hospital [Tokyo], Ajou University, University of Ottawa [Ottawa], Saga-ken Medical Centre Koseikan [Saga, Japan] (SMCK), University of South Alabama, Konkuk University [Seoul], Royal Free Hospital [London, UK], Hospital Clinico Universitario de Valladolid [Castilla y León, Spain] (HCUV), Universidad de Valladolid [Valladolid] (UVa), Instituto de Ciencia de Materiales de Aragón [Saragoza, España] (ICMA-CSIC), University of Zaragoza - Universidad de Zaragoza [Zaragoza], Hospital Clínic de Barcelona [Catalonia, Spain], Centro Hospitalar Universitário de São João [Porto], Christchurch Hospital [Christchurch, New Zealand] (CH), University Hospital Basel [Basel], University of Southern California (USC), Kohnan Hospital - Sendai [Miyagi, Japan], University of Texas Southwestern Medical Center [Dallas], Nara City Hospital [Nara, Japan] (NCH), Toyonaka Municipal Hospital [Osaka, Japan] (TMH), Kagoshima City Hospita [Kagoshima, Japan] (KCH), Texas Tech University System [Lubbock, TX, USA] (TTUS), University of Saskatchewan [Saskatoon] (U of S), National Institute of Information and Communications Technology [Tokyo, Japan] (NICT), Royal Prince Alfred Hospital [Camperdown, Australia] (RPAH), Banner Desert Medical Center [Mesa, AZ, USA] (BDMC), Japanese Red Cross Matsue Hospital [Shimane, Japan] (JRCMH), Shiroyama Hospital [Osaka, Japan] (SH), Niigata City General Hospital [Niigata, Japan] (NCGH), Sugimura Hospital [Kumamoto, Japan] (SH), Kawasaki Medical School [Kurashiki, Japan] (KMS), Osaka Red Cross Hospital [Osaka, Japan] (ORCH), Université de Tsukuba = University of Tsukuba, Saiseikai Central Hospital [Tokyo, Japan] (SCH), Kinikyo Chuo Hospital - Sapporo [Hokkaido, Japan] (KCHS), NTT Medical Center Tokyo [Tokyo, Japan] (NTTMCT), Yokohama Shintoshi Neurosurgical Hospital [Yokohama, Japan]. (YSNH), Osaka General Medical Center [Osaka, Japan] (OGMC), University of Miami Leonard M. Miller School of Medicine (UMMSM), Bon Secours Mercy Health System [Toledo, OH, USA] (BSMHS), Maoming City Hospital [Guandong, China] (MCH), Miami Cardiac & Vascular Institute [Miami, FL, USA] (MC&VI), Hackensack University Medical Center [Hackensack], David Geffen School of Medicine [Los Angeles], University of California [Los Angeles] (UCLA), University of California (UC)-University of California (UC), University of Tennessee [Chattanooga] (UTC), The University of Texas at San Antonio (UTSA), Mianyang 404 Hospital [Sichuan, China] (M404H), Siriraj Hosital - Mahidol University [Bangkok, Thailand] (SHMU), SUNY Upstate Medical University, State University of New York (SUNY), Royal North Shore Hospital (RNSH), The University of Texas Rio Grande Valley [Harlingen, TX, USA] (UTRGV), Khoula Hospital [Muscat, Oman] (Ministry of Health - KH), University of Michigan [Ann Arbor], University of Michigan System, University of South Florida [Tampa] (USF), Henry Ford Health System [Detroit, MI, USA] (HFHS), Metropolitan Hospital [Piraeus, Greece] (MH), National and Kapodistrian University of Athens (NKUA), Maine Medical Center, Dartmouth Hitchcock Medical Center [Lebanon, NH, USA] (DHMC), Centro Universitário Feevale (BRAZIL), The Valley Hospital [Ridgewood, NJ, USA] (TVH), St Joseph's University Medical Center [Paterson, NJ, USA] (StJUMC), Christian Medical College and Hospital Ludhiana [Punjab, India] (CMCHL), Universidad del Desarrollo, University Graduate School of Medicine [Osaka, Japan], Tokushima University, Universidade Federal de São Paulo, Istanbul Aydin University [İstanbul, Turkey] (IAU), Swedish Medical Center [Englewood, CO, USA] (SMC), Bayhealth Medical Center [Dover, DE, USA] (BMC), Saiseikai Fukuoka General Hospital [Fukuoka, Japan] (SFGH), Osaka Rosai Hospital - Sakai [Osaka, Japan] (ORHS), King Saud University [Riyadh] (KSU), Mount Sinai Health System, University of Calgary, Huzhou University [Zhejiang], The Affiliated Hospital of Southwest Medical University - Luzhou [Sichuan, China] (TAHSMUL), Yijishan Hospital of Wannan Medical College [Wuhu, Anhui, China] (YHWMC), University of Toledo, WellStar Health System [Marietta, GA, USA] (WHS), Institut National de la Recherche Scientifique [Québec] (INRS), Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR CHUM), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM), SVIN COVID-19 Registry, the Middle East North Africa Stroke and Interventional Neurotherapies Organization (MENA-SINO), Japanese Society of Vascular and Interventional Neurology Society (JVIN), University of California [San Francisco] (UCSF), University of California, Yale University School of Medicine, University of São Paulo (USP), and University of California-University of California

Subjects
[SDV]Life Sciences [q-bio], COVID-19, Subarachnoid Hemorrhage* / diagnostic imaging, 030204 cardiovascular system & hematology, Intracranial Aneurysm* / therapy, lcsh:RC346-429, 0302 clinical medicine, Pandemic, Myocardial infarction, Prospective Studies, Stroke, Original Research, 3. Good health, [SDV] Life Sciences [q-bio], Treatment Outcome, Intracranial Aneurysm* / diagnostic imaging, Cardiology, Subarachnoid haemorrhage, haemorrhage, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Subgroup analysis, subarachnoid, Intracranial Aneurysm* / epidemiology, 03 medical and health sciences, Aneurysm, Internal medicine, medicine, Humans, coil, cardiovascular diseases, Pandemics, lcsh:Neurology. Diseases of the nervous system, Retrospective Studies, business.industry, SARS-CoV-2, Intracranial Aneurysm, Subarachnoid Hemorrhage, medicine.disease, infection, nervous system diseases, Mechanical thrombectomy, Cross-Sectional Studies, aneurysm, Neurology (clinical), Subarachnoid Hemorrhage* / epidemiology, business, 030217 neurology & neurosurgery
Abstract

BackgroundDuring the COVID-19 pandemic, decreased volumes of stroke admissions and mechanical thrombectomy were reported. The study’s objective was to examine whether subarachnoid haemorrhage (SAH) hospitalisations and ruptured aneurysm coiling interventions demonstrated similar declines.MethodsWe conducted a cross-sectional, retrospective, observational study across 6 continents, 37 countries and 140 comprehensive stroke centres. Patients with the diagnosis of SAH, aneurysmal SAH, ruptured aneurysm coiling interventions and COVID-19 were identified by prospective aneurysm databases or by International Classification of Diseases, 10th Revision, codes. The 3-month cumulative volume, monthly volumes for SAH hospitalisations and ruptured aneurysm coiling procedures were compared for the period before (1 year and immediately before) and during the pandemic, defined as 1 March–31 May 2020. The prior 1-year control period (1 March–31 May 2019) was obtained to account for seasonal variation.FindingsThere was a significant decline in SAH hospitalisations, with 2044 admissions in the 3 months immediately before and 1585 admissions during the pandemic, representing a relative decline of 22.5% (95% CI −24.3% to −20.7%, pInterpretationThere was a relative decrease in the volume of SAH hospitalisations, aneurysmal SAH hospitalisations and ruptured aneurysm embolisations during the COVID-19 pandemic. These findings in SAH are consistent with a decrease in other emergencies, such as stroke and myocardial infarction.

Published
2021

9. A call to action for new global approaches to cardiovascular disease drug solutions

Author

Carolyn S.P. Lam, Grant R Drummond, Calum A. MacRae, Joseph C. Wu, Gemma A. Figtree, Filippo Crea, David G. Harrison, James L. Januzzi, Barbara Casadei, Rebecca H. Ritchie, Maciej Tomaszewski, Faiez Zannad, Robert M. Califf, Frank Misselwitz, Jane E. Freedman, Bronwyn A. Kingwell, Derek J. Hausenloy, Tetsuji Miura, Keith Broadfoot, Junjie Xiao, Joseph A. Hill, Tomasz J. Guzik, Royal North Shore Hospital (RNSH), The University of Sydney, Clinical Committee, National Heart Foundation of Australia, Radcliffe Department of Medicine [Oxford], University of Oxford, Oxford NIHR Biomedical Research Centre, British Heart Foundation Centre of Research Excellence [Oxford, Royaume-Uni] (Oxford BHF-CRE), Verily Life Sciences Inc, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), La Trobe University [Melbourne], University of Massachusetts Medical School [Worcester] (UMASS), University of Massachusetts System (UMASS), University of Glasgow, Vanderbilt University School of Medicine [Nashville], National University of Singapore (NUS), University of Texas Southwestern Medical Center, Massachusetts General Hospital [Boston], CSL Ltd, National Heart Centre Singapore (NHCS), Duke-National University of Singapore Graduate Medical School, Brigham and Women’s Hospital [Boston, MA], Harvard Medical School [Boston] (HMS), Bayer AG, Pharmaceuticals Division, Sapporo Medical University, Monash Institute of Pharmaceutical Sciences [Parkville] (MIPS), Faculty of Pharmacy and Pharmaceutical Sciences - Monash University [Parkville], Monash university-Monash university, Faculty of Biology, Medicine and Health [Manchester, UK], University of Manchester [Manchester], Stanford Cardiovascular Institute, University of Shanghai [Shanghai], Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), BOZEC, Erwan, British Heart Foundation Centre of Research Excellence, University of Cambridge, CSL Limited, and Duke-NUS Medical School [Singapore]

Subjects
Drug, Arterial disease, Therapeutic target, media_common.quotation_subject, precision medicine, heart failure, Heart failure, Disease, 030204 cardiovascular system & hematology, Cardiovascular, drug discovery, 03 medical and health sciences, pharmacotherapy, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Physiology (medical), therapeutics, Medicine, Humans, 030212 general & internal medicine, organoids, 030304 developmental biology, media_common, 0303 health sciences, Multi-omics, business.industry, Drug discovery, cardiovascular, Precision medicine, Atherosclerosis, Pharmacotherapy, drug therapy, Call to action, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Organoids, Incentive, Risk analysis (engineering), Pharmaceutical Preparations, Cardiovascular Diseases, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, cardiovascular system, atherosclerosis, Cardiology and Cardiovascular Medicine, business, Product identification, Biomarkers
Abstract

Whilst we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there reduces the incentive for industry to invest, despite the enormous burden of disease and potential size of market. There are tremendous opportunities with improved phenotyping of patients currently batched together in syndromic ‘buckets’. Use of advanced imaging and molecular markers may allow stratification of patients in a manner more aligned to biological mechanisms that can, in turn, be targeted by specific approaches developed using high-throughput molecular technologies. Unbiased ‘omic’ approaches enhance the possibility of discovering completely new mechanisms in such groups. Furthermore, advances in drug discovery platforms, and models to study efficacy and toxicity more relevant to the human disease, are valuable. Re-imagining the relationships among discovery, translation, evaluation, and implementation will help reverse the trend away from investment in the cardiovascular space, establishing innovative platforms and approaches across the full spectrum of therapeutic development.

Published
2021

10. Dual mobility cups for total hip arthroplasty: tips and tricks

Author

Thomas Neri, Cécile Batailler, Antonio Klasan, Rémi Philippot, Bertrand Boyer, Frédéric Farizon, Sébastien Lustig, Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM ), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), INSERM U1059, SAINBIOSE - Santé, Ingénierie, Biologie, Saint-Etienne (SAINBIOSE-ENSMSE), Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Ingénierie et Santé (CIS-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Service de Chirurgie Orthopédique [Centre Albert Trillat], Centre Albert Trillat [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Royal North Shore Hospital (RNSH), Hospices Civils de Lyon (HCL), Cadic, Ifsttar, Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Centre Ingénierie et Santé (CIS-ENSMSE), and Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
medicine.medical_specialty, [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery, tricks, Context (language use), tips, DUAL MOBILITY CUP, Review Article, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, 03 medical and health sciences, 0302 clinical medicine, lcsh:Orthopedic surgery, Medicine, Orthopedics and Sports Medicine, Complication rate, Medical physics, 030212 general & internal medicine, SURGICAL TECHNIQUE, 030222 orthopedics, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, business.industry, Implant compatibility, TOTAL HIP ARTHROPLASTY, Dual mobility, Special Issue: "HIP and KNEE Replacement" Guest Editors: C Batailler, S Lustig, J Caton, lcsh:RD701-811, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Orthopedic surgery, TIP, Surgery, business, TRICK, Total hip arthroplasty
Abstract

Since its creation in 1974, the Dual Mobility Cup (DMC) has been gaining in popularity, especially in the past decade. This intensive use could lead to inappropriate use and consequently to an increased complication rate. Compliance with conceptual requirements and surgical techniques will prevent the occurrence of complications that can be wrongly attributed to implants. In this context, we feel that it is essential to share our tips and tricks as well as an overview and an explanation of common errors, based on more than 45 years of clinical and research experience. From basic principles, including indications, implant choice and implant compatibility, to surgical tips, in this article orthopedic surgeons will find a practical overview of DMC in order to use it safely and with confidence.

Published
2020

11. CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome

Author

Marius Ringelstein, L. M. Yshii, Ilka Kleffner, Stephen W. Reddel, Brigitte Wildemann, Todd A. Hardy, Markus Schwaninger, Guillaume Martin-Blondel, Nicholas Schwab, Delphine Loussouarn, John Parratt, Marc Pawlitzki, Henrike Plate, Eduardo Beltrán, Catharina C. Gross, Anna R. Tröscher, Tanja Kuhlmann, Tilman Schneider-Hohendorf, Klaus Dornmair, Jan Dörr, Roland S. Liblau, Urvashi Bhatia, Hans Lassmann, Sven G. Meuth, Luisa Klotz, Sebastian Herich, Markus Kraemer, Jan Bauer, Céline Meyer, David-Axel Laplaud, Wolfgang Brück, Romana Höftberger, Michael Barnett, Michael E. Buckland, Andreas Schulte-Mecklenbeck, Heinz Wiendl, University Hospital Münster - Universitaetsklinikum Muenster [Germany] (UKM), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Medizinische Universität Wien = Medical University of Vienna, Institute for Experimental and Clinical Pharmacology and Toxicology [Lübeck, Germany], University of Lübeck [Germany], Institute of Neuropathology [Göttingen, Germany], University Medical Center Göttingen (UMG), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service d’Anatomopathologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Royal North Shore Hospital [Sydney, Australia], Microsoft Research [Redmond], Microsoft Corporation [Redmond, Wash.], The University of Sydney, Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Heidelberg, Medical Faculty, University of Vienna [Vienna], Institute of Clinical Neuroimmunology [Munich, Germany], Ludwig-Maximilians University [Munich] (LMU), Service des maladies infectieuses et tropicales [Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Le Bihan, Sylvie, MECANISMES INTEGRES DE L'INFLAMMATION - Infiltration tissulaire des macrophages et inflammation : identification d'inhibiteurs de la migration cellulaire en trois dimensions. - - MigreFlame2010 - ANR-10-MIDI-0013 - MI2 - VALID, Blanc 2013 - Migration des lymp^hocytes T CD8 T dans le système nerveux central - - T cell Mig2013 - ANR-13-BSV3-0003 - Blanc 2013 - VALID, Westfälische Wilhelms-Universität Münster = University of Münster (WWU), Ruhr University Bochum (RUB), Universitätsklinikum Knappschaftskrankenhaus = University Hospital Knappschaftskrankenhaus [Bochum], Universität zu Lübeck = University of Lübeck [Lübeck], Service de neurologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Royal North Shore Hospital (RNSH), Royal Prince Alfred Hospital [Sydney, Australia], Ludwig-Maximilians-Universität München (LMU), Munich Cluster for systems neurology [Munich] (SyNergy), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM)-Ludwig-Maximilians-Universität München (LMU), Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), ANR-10-MIDI-0013,MigreFlame,Infiltration tissulaire des macrophages et inflammation : identification d'inhibiteurs de la migration cellulaire en trois dimensions.(2010), ANR-13-BSV3-0003,T cell Mig,Migration des lymp^hocytes T CD8 T dans le système nerveux central(2013), Centre de Physiopathologie Toulouse Purpan (CPTP - U1043 INSERM - UMR5282 CNRS - UT3), University Medical Center Göttingen [Germany], Heinrich-Heine-Universität Düsseldorf [Düsseldorf], Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin, and Service des maladies infectieuses et tropicales[Toulouse]

Subjects
0301 basic medicine, MESH: Integrin alpha4 / metabolism, [SDV]Life Sciences [q-bio], Neuroimmunology, General Physics and Astronomy, Autoimmunity, 0302 clinical medicine, Natalizumab, Cytotoxic T cell, MESH: Animals, lcsh:Science, MESH: Endothelium, Vascular / drug effects, Multidisciplinary, MESH: Central Nervous System / immunology, MESH: Endothelium, Vascular / pathology, MESH: Microvessels / pathology, 3. Good health, [SDV] Life Sciences [q-bio], medicine.anatomical_structure, MESH: Cell Adhesion / drug effects, [SDV.IMM]Life Sciences [q-bio]/Immunology, Function and Dysfunction of the Nervous System, MESH: Central Nervous System / pathology, medicine.drug, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH: Mice, Transgenic, Science, Central nervous system, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Immune system, MESH: Microvessels / immunology, medicine, MESH: Cell Adhesion / immunology, Neuroinflammation, Susac Syndrome, MESH: Central Nervous System / blood suppl, MESH: Humans, business.industry, MESH: Adult, General Chemistry, MESH: Integrin alpha4 / antagonists & inhibitors, MESH: Male, Granzyme B, Susac syndrome, neuro-inflammation, endotheliopathy, 030104 developmental biology, Immunology, lcsh:Q, MESH: Endothelium, Vascular / immunology, MESH: Microvessels / drug effects, MESH: Disease Models, Animal, business, MESH: Female, 030217 neurology & neurosurgery, CD8
Abstract

International audience; Neuroinflammation is often associated with blood-brain-barrier dysfunction, which contributes to neurological tissue damage. Here, we reveal the pathophysiology of Susac syndrome (SuS), an enigmatic neuroinflammatory disease with central nervous system (CNS) endotheliopathy. By investigating immune cells from the blood, cerebrospinal fluid, and CNS of SuS patients, we demonstrate oligoclonal expansion of terminally differentiated activated cytotoxic CD8+ T cells (CTLs). Neuropathological data derived from both SuS patients and a newly-developed transgenic mouse model recapitulating the disease indicate that CTLs adhere to CNS microvessels in distinct areas and polarize granzyme B, which most likely results in the observed endothelial cell injury and microhemorrhages. Blocking T-cell adhesion by anti-α4 integrin-intervention ameliorates the disease in the preclinical model. Similarly, disease severity decreases in four SuS patients treated with natalizumab along with other therapy. Our study identifies CD8+ T-cell-mediated endotheliopathy as a key disease mechanism in SuS and highlights therapeutic opportunities.disease severity decreases in four SuS patients treated with natalizumab along with other therapy. Our study identifies CD8+ T-cell-mediated endotheliopathy as a key disease mechanism in SuS and highlights therapeutic opportunities.

Published
2019

12. Developing a Preliminary Definition and Domains of Flare in Knee and Hip Osteoarthritis (OA): Consensus Building of the Flare-in-OA OMERACT Group

Author

Elisabeth Spitz, Hakima Manseur, Michel Cembalo, Hema Urban, Annica Barcenilla-Wong, Camille Alleyrat, Camille Ricatte, Philip G. Conaghan, Gillian A. Hawker, Lyn March, Bruno Fautrel, Claudia Rutherford, Thomas Buttel, Amandine Schoumacker, David J. Hunter, Marita Cross, Francis Guillemin, CIC-Nancy, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy]-Institut National de la Santé et de la Recherche Médicale (INSERM), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Institute of Bone & Joint Research, Royal North Shore Hospital (RNSH)-The University of Sydney, Service de Rhumatologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Section of Musculoskeletal Diseasee, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Johns Hopkins University (JHU), Department of Statistics, Penn State University, University of Pennsylvania [Philadelphia], Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
musculoskeletal diseases, medicine.medical_specialty, Consensus, Exacerbation, Knee Joint, Immunology, education, Osteoarthritis, Osteoarthritis, Hip, law.invention, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, law, medicine, Hip osteoarthritis, Immunology and Allergy, Humans, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, 030203 arthritis & rheumatology, Health professionals, business.industry, Osteoarthritis, Knee, medicine.disease, Physical therapy, Hip Joint, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Psychological aspects, business, human activities, Flare
Abstract

Flare in knee and hip osteoarthritis (OA) is more than just an exacerbation of pain. Unstructured, semistructured, and focus group interviews followed by Delphi surveys with patients and health professionals (HP) generated candidate domains of an OA flare. Content analysis of interviews with 29 patients and 16 HP extracted 180 statements, which were grouped into 9 clusters. Delphi consensus with 50 patients (Australia, Canada, and France) and 116 HP (17 countries on 4 continents) identified 5 flare domains: pain, swelling, stiffness, psychological aspects, and effect of symptoms. Elements for a preliminary definition of an OA flare are proposed. Registered at clinicaltrials.govNCT02892058.

Published
2019

13. Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative

Author

Nielsen, S.M., Tugwell, P., Wit, M.P.T. de, Boers, M., Beaton, D.E., Woodworth, T.G., Escorpizo, R., Shea, B., Toupin-April, K., Guillemin, F., Strand, V., Singh, J.A., Kloppenburg, M., Furst, D.E., Wells, G.A., Smolen, J.S., Vesely, R., Boonen, A., Storgaard, H., Voshaar, M., March, L., Christensen, R., Contextual Factors Working Grp, University of Ottawa [Ottawa] (uOttawa), Department of Clinical Epidemiology and Biostatistics, VU University Medical Center [Amsterdam], Institute for Work and Health (IWH), University of Toronto-St. Michael's Hospital-Institute of Medical Sciences, University of California [Los Angeles] (UCLA), University of California, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Stanford University School of Medicine [Stanford], Stanford University [Stanford], Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Maastricht University Medical Center (MUMC), Maastricht University [Maastricht], Institute of Bone & Joint Research, Royal North Shore Hospital (RNSH)-The University of Sydney, The Parker Institute, University of Copenhagen = Københavns Universitet (KU), Interne Geneeskunde, MUMC+: MA Reumatologie (9), RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation, Ethics, Law & Medical humanities, APH - Methodology, Epidemiology and Data Science, University of Ottawa [Ottawa], Stanford School of Medicine [Stanford], Stanford Medicine, Stanford University-Stanford University, Maastricht University Medical Centre (MUMC), and Psychology, Health & Technology

Subjects
RHEUMATIC DISEASES, medicine.medical_specialty, Consensus, Immunology, Applied psychology, Session (web analytics), 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Risk Factors, Internal medicine, Outcome Assessment, Health Care, Humans, Immunology and Allergy, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, 030203 arthritis & rheumatology, OUTCOMES, business.industry, OMERACT, Special Interest Group, Prognosis, n/a OA procedure, Clinical trial, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, CLINICAL TRIALS, Healthcare system
Abstract

Objective.The Contextual Factors Working Group aims to provide guidance on addressing contextual factors in rheumatology trials within OMERACT.Methods.During the Special Interest Group session at OMERACT 2018, preliminary results were presented from a case scenario survey and semistructured interviews, including contextual factors mentioned in these. A group-based exercise sought to identify and rank important generic contextual factors.Results.A total of 79 candidate factors were listed. Across the 3 groups, gender/sex, comorbidities, and the healthcare system were ranked as most important.Conclusion.The identified important contextual factor domains may be considered a provisional list pending further research.

Published
2019

14. Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017

Author

Anne E. Ashford, Alan Tennant, Nigel K Arden, Robin Christensen, Maarten de Wit, Beverley Shea, Christoph Ladel, Maarten Boers, Toby O. Smith, Thomas Buttel, Ewa M. Roos, Ulrike Kaiser, Lyn March, Marc C. Hochberg, G.A. Hawker, Francis Guillemin, Philip G. Conaghan, Paula R Williamson, Caroline B. Terwee, Thomas J. Schnitzer, Gurdyal Kalsi, David J. Hunter, Tuhina Neogi, Michael Mansfield, Peter Tugwell, Margreet Kloppenburg, Ali Mobasheri, Richard F. Loeser, APH - Methodology, Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Department of Statistics, Penn State University, University of Pennsylvania [Philadelphia], Institute of Bone & Joint Research, Royal North Shore Hospital (RNSH)-The University of Sydney, VU University Medical Center [Amsterdam], The Parker Institute, University of Copenhagen = Københavns Universitet (KU), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), EMGO Institute Health and Care Research, VU University Amsterdam Medical Center, University of Southern Denmark (SDU), Department of Rheumatology and Clinical Epidemiology, Leiden University Medical Center (LUMC), School of Veterinary Medicine and Science, University of Nottingham, UK (UON), University of Oxford [Oxford], Medical Care Clinical Center [Baltimore, MD, USA], VA Maryland Health Care System [Baltimore, MD, USA], University of Ottawa [Ottawa], Section of Musculoskeletal Diseasee, and University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit

Subjects
musculoskeletal diseases, medicine.medical_specialty, ADOPTION, Arthroplasty, Replacement, Hip, Immunology, TRIAL REGISTRATION, Osteoarthritis, Physical function, Osteoarthritis, Hip, law.invention, 03 medical and health sciences, 0302 clinical medicine, DOMAIN, Randomized controlled trial, Rheumatology, law, Internal medicine, medicine, Immunology and Allergy, Humans, 030212 general & internal medicine, Trial registration, Arthroplasty, Replacement, Knee, Osteoarthritis, Knee/surgery, Randomized Controlled Trials as Topic, Core (anatomy), business.industry, Osteoarthritis, Hip/surgery, Outcome measures, OMERACT, 1103 Clinical Sciences, Osteoarthritis, Knee, medicine.disease, Arthritis & Rheumatology, 3. Good health, Treatment Outcome, 1117 Public Health And Health Services, CORE OUTCOME SET, 1107 Immunology, Physical therapy, Quality of Life, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, 030217 neurology & neurosurgery
Abstract

Objective.To assess the uptake of the OMERACT-OARSI (Outcome Measures in Rheumatology- Osteoarthritis Research Society International) core outcome set (COS) domains in hip and/or knee osteoarthritis (OA) trials.Methods.There were 382 trials of hip and/or knee OA identified from the ClinicalTrial.gov registry from 1997 to 2017. Frequency of COS adoption was assessed by year and per 5-yearly phases.Results.COS adoption decreased from 61% between 1997 and 2001 to 38% between 2012 and 2016. Pain (95%) and physical function (86%) were most consistently adopted. Patient’s global assessment (48%) was the principal missing domain.Conclusion.Limited adoption of the COS domains indicates that further consideration to improve uptake is required.

Published
2018

15. An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group

Author

Dorcas E. Beaton, Amye L. Leong, Caroline A Flurey, Marieke Voshaar, Annelies Boonen, Thasia G. Woodworth, Daniel E. Furst, Suzanne M M Verstappen, Christoph Pohl, P. Tugwell, Nataliya Milman, Monika E. Finger, Sabrina Mai Nielsen, Francis Guillemin, Reuben Escorpizo, Lyn March, Margreet Kloppenburg, Rieke Alten, Robin Christensen, Swiss Paraplegic Research = Schweizer Paraplegiker-Stiftung, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], University of California [Los Angeles] (UCLA), University of California, The Parker Institute, University of Copenhagen = Københavns Universitet (KU), Healthy Motivation, University of Twente [Netherlands], Schlosspark Klinik Berlin, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Department of Rheumatology and Clinical Epidemiology, Leiden University Medical Center (LUMC), Institute for Work and Health (IWH), University of Toronto-St. Michael's Hospital-Institute of Medical Sciences, University of Ottawa [Ottawa], Institute of Bone & Joint Research, Royal North Shore Hospital (RNSH)-The University of Sydney, Interne Geneeskunde, MUMC+: MA Reumatologie (9), and RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation

Subjects
Research design, Applied psychology, Psychological intervention, law.invention, 0302 clinical medicine, International Classification of Functioning, Disability and Health, Randomized controlled trial, law, Immunology and Allergy, Medicine, 030212 general & internal medicine, Patient reported outcomes, Randomized Controlled Trials as Topic, FILTER 2.0, RHEUMATOLOGY, Randomized controlled trails, PRODUCTIVITY, Operational definition, Contextual, ANKYLOSING-SPONDYLITIS, OMERACT, CONTEXTUAL, OUTCOME MEASUREMENT SETS, FAMILY, 3. Good health, Research Design, Data Interpretation, Statistical, EFFECT MODIFIER, Omeract, ONTEXTUAL, CLINICAL-TRIALS, INTERVENTIONS, Consensus, Immunology, MATTERS, 03 medical and health sciences, Rheumatology, Rheumatic Diseases, Humans, Patient Reported Outcome Measures, 030203 arthritis & rheumatology, RANDOMIZED CONTROLLED TRIALS, FUTURE-RESEARCH, business.industry, Special Interest Group, Effect modifier, MODEL, Clinical trial, PATIENT-REPORTED OUTCOMES, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Working group, business
Abstract

Objective.The importance of contextual factors (CF) for appropriate patient-specific care is widely acknowledged. However, evidence in clinical trials on how CF influence outcomes remains sparse. The 2014 Outcome Measures in Rheumatology (OMERACT) Handbook introduced the role of CF in outcome assessment and defined them as “potential confounders and/or effect modifiers of outcomes in randomized controlled trials.” Subsequently, the CF Methods Group (CFMG) was formed to develop guidance on how to address CF in clinical trials.Methods.First, the CFMG conducted an e-mail survey of OMERACT working groups (WG) to analyze how they had addressed CF in outcome measurement so far. The results facilitated an informed discussion at the OMERACT 2016 CFMG Special Interest Group (SIG) session, with the aim of gaining preliminary consensus regarding an operational definition of CF and to make a first selection of potentially relevant CF.Results.The survey revealed that the WG had mostly used the OMERACT Handbook and/or the International Classification of Functioning, Disability and Health (ICF) definition. However, significant heterogeneity was found in the methods used to identify, refine, and categorize CF candidates. The SIG participants agreed on using the ICF as a framework along with the OMERACT Handbook definition. A list with 28 variables was collected including person-related factors and physical and social environments. Recommendations from the SIG guided the CFMG to formulate 3 preliminary projects on how to identify and analyze CF.Conclusion.New methods are urgently needed to assist researchers to identify and characterize CF that significantly influence the interpretation of results in clinical trials. The CFMG defined first steps to develop further guidance.

Published
2017

16. Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report

Author

Thasia G. Woodworth, Daniel E. Furst, Robin Christensen, Anne Lyddiatt, Vivian P. Bykerk, Clifton O. Bingham, Alfons den Broeder, Sarah Hewlett, Pamela Montie, Francis Guillemin, Christoph Pohl, Rieke Alten, Bruno Fautrel, Marieke Voshaar, Susan J. Bartlett, Skye Barbic, Lyn March, Amye L. Leong, Ernest Choy, McGill University = Université McGill [Montréal, Canada], University of British Columbia (UBC), Hospital for Special Surgery, Cardiff University, Schlosspark Klinik Berlin, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], The Parker Institute, University of Copenhagen = Københavns Universitet (KU), Sint Maartenskliniek, CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of California [Los Angeles] (UCLA), University of California, Université de Lorraine (UL), University of the West of England [Bristol] (UWE Bristol), Healthy Motivation, The University of Sydney, Institute of Bone & Joint Research, Royal North Shore Hospital (RNSH)-The University of Sydney, Johns Hopkins University (JHU), University of Twente [Netherlands], and FLARE-RA

Subjects
medicine.medical_specialty, Psychometrics, Immunology, PATIENT-REPORTED OUTCOME, Sensitivity and Specificity, Severity of Illness Index, Article, law.invention, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Randomized controlled trial, DISEASE EXACERBATION, law, Rating scale, Surveys and Questionnaires, medicine, Content validity, Humans, Immunology and Allergy, 030212 general & internal medicine, RHEUMATOID ARTHRITIS, ComputingMilieux_MISCELLANEOUS, Pain Measurement, 030203 arthritis & rheumatology, Rasch model, business.industry, Reproducibility of Results, Construct validity, OMERACT, Differential item functioning, Physical therapy, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Patient-reported outcome, Observational study, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Symptom Assessment, business
Abstract

Objective.The Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis (RA) Flare Group was established to develop a reliable way to identify and measure RA flares in randomized controlled trials (RCT). Here, we summarized the development and field testing of the RA Flare Questionnaire (RA-FQ), and the voting results at OMERACT 2016.Methods.Classic and modern psychometric methods were used to assess reliability, validity, sensitivity, factor structure, scoring, and thresholds. Interviews with patients and clinicians also assessed content validity, utility, and meaningfulness of RA-FQ scores.Results.People with RA in observational trials in Canada (n = 896) and France (n = 138), and an RCT in the Netherlands (n = 178) completed 5 items (11-point numerical rating scale) representing RA Flare core domains. There was moderate to high evidence of reliability, content and construct validity, and responsiveness. Factor analysis supported unidimensionality. Rasch analysis showed acceptable fit to the Rasch model, with items and people covering a broad measurement continuum and evidence of appropriate targeting of items to people, ordered thresholds, minimal differential item functioning by language, sex, or age. A summative score across items is defensible, yielding an interval score (0–50) where higher scores reflect worsening flare. The RA-FQ received endorsement from 88% of attendees that it passed the OMERACT Filter 2.0 “Eyeball Test” for instrument selection.Conclusion.The RA-FQ has been developed to identify and measure RA flares. Its review through OMERACT Filter 2.0 shows evidence of reliability, content and construct validity, and responsiveness. These properties merit its further validation as an outcome for clinical trials.

Published
2017

17. Impact of obesity and epicardial fat on early left atrial dysfunction assessed by cardiac MRI strain analysis

Author

Rachel T. McGrath, Rebecca Kozor, Nadjia Kachenoura, Kathryn M. Broadhouse, Fraser M. Callaghan, Samantha L. Hocking, Sarah J. Glastras, Gemma A. Figtree, Morgane Evin, Jerome Lamy, Stuart M. Grieve, Greg Fulcher, Alban Redheuil, Laboratoire d'Imagerie Biomédicale (LIB), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Royal North Shore Hospital (RNSH), Laboratoire d'Imagerie Biomédicale [Paris] (LIB), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), and BMC, BMC

Subjects
Male, Obesity and type 2, Endocrinology, Diabetes and Metabolism, [SDV]Life Sciences [q-bio], Adipose tissue, Type 2 diabetes, 030204 cardiovascular system & hematology, Ventricular Function, Left, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Diastole, Risk Factors, Original Investigation, Adiposity, medicine.diagnostic_test, Middle Aged, 3. Good health, [SDV] Life Sciences [q-bio], Adipose Tissue, Cardiology, Cardiac dysfunction, Diastolic dysfunction, Atrial Function, Left, Female, Cardiology and Cardiovascular Medicine, Pericardium, Algorithms, Adult, medicine.medical_specialty, Heart Diseases, Magnetic Resonance Imaging, Cine, Fat distribution, 03 medical and health sciences, Predictive Value of Tests, Internal medicine, Diabetes mellitus, Image Interpretation, Computer-Assisted, medicine, Humans, Obesity, Angiology, business.industry, Case-control study, Magnetic resonance studies, Magnetic resonance imaging, medicine.disease, Early Diagnosis, Diabetes Mellitus, Type 2, Case-Control Studies, business
Abstract

Background Diastolic dysfunction is a major cause of morbidity in obese individuals. We aimed to assess the ability of magnetic resonance imaging (MRI) derived left atrial (LA) strain to detect early diastolic dysfunction in individuals with obesity and type 2 diabetes, and to explore the association between cardiac adipose tissue and LA function. Methods Twenty patients with obesity and T2D (55 ± 8 years) and nineteen healthy controls (48 ± 13 years) were imaged using cine steady state free precession and 2-point Dixon cardiovascular magnetic resonance. LA function was quantified using a feature tracking technique with definition of phasic longitudinal strain and strain rates, as well as radial motion fraction and radial velocities. Results Systolic left ventricular size and function were similar between the obesity and type 2 diabetes and control groups by MRI. All patients except four had normal diastolic assessment by echocardiography. In contrast, measures of LA function using magnetic resonance feature tracking were uniformly altered in the obesity and type 2 diabetes group only. Although there was no significant difference in intra-myocardial fat fraction, Dixon 3D epicardial fat volume(EFV) was significantly elevated in the obesity and type 2 diabetes versus control group (135 ± 31 vs. 90 ± 30 mL/m2, p Conclusions LA MRI-strain may be a sensitive tool for the detection of early diastolic dysfunction in individuals with obesity and type 2 diabetes and correlated with BMI and epicardial fat supporting a possible association between adiposity and LA strain. Trials Registration Australian New Zealand Clinical Trials Registry No. ACTRN12613001069741

Published
2016

18. Biomechanical properties of the plantar flexor muscle-tendon complex 6 months post-rupture of the achilles tendon

Author

McNair, Peter, Nordez, Antoine, Olds, Margie, Young, Simon, Cornu, Christophe, Auckland University of Technology (AUT), Motricité, interactions, performance EA 4334 / Movement - Interactions - Performance (MIP), Université de Nantes - UFR des Sciences et Techniques des Activités Physiques et Sportives (UFR STAPS), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Le Mans Université (UM), and Royal North Shore Hospital (RNSH)

Subjects
body regions, [SDV.MHEP.AHA]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]
Abstract

International audience; We compared the effects of a non-weight bearing protocol (NWB) and a weight bearing (WB) protocol on energy stored, stiffness, and shock absorption in the plantar flexor muscle–tendon unit of patients managed non-operatively following an Achilles tendon rupture. Thirty-eight subjects were randomized to a WB cast fitted with a Bohler iron or a traditional non-weight-bearing cast. At a 6-month follow-up, a biomechanical assessment utilizing an isokinetic dynamometer allowed measurement of peak passive torque, energy stored, shock absorption, and stiffness. The WB group had greater peak passive torque (∼20%). Irrespective of group, peak passive torque in unaffected legs was greater (∼26%) than affected legs. Across the groups, energy stored in the NWB group was 74% of the WB group. The energy stored in affected legs was 80% of that in unaffected legs. Shock absorption was not significantly different across legs or groups. Irrespective of group, affected legs had significantly less stiffness (20–40%). While the augmentation of plaster with a Bohler iron to allow increased weight bearing had positive effects, deficits in affected compared to unaffected legs irrespective of group were notable, and should be addressed prior to participation in vigorous physical activities.

Published
2013

19. HACEK Infective Endocarditis: Characteristics and Outcomes from a Large, Multi-National Cohort

Author

Chambers, Stephen T, Murdoch, David, Morris, Arthur, Holland, David, Pappas, Paul, Almela, Manel, Fernández Hidalgo, Nuria, Almirante, Benito, Bouza, Emilio, Forno, Davide, Rio, Ana del, Hannan, Margaret M., Harkness, John, Kanafani, Zeina A., Lalani, Tahaniyat, Lang, Selwyn, Raymond, Nigel, Read, Kerry, Vinogradova, Tatiana, Woods, Christopher W., Wray, Dannah, Corey, G. Ralph, Chu, Vivian H., Clara, Liliana, Sanchez, Marisa, Nacinovich, Francisco, Oses, Pablo Fernandez, Ronderos, Ricardo, Sucari, Adriana, Thierer, Jorge, Casabé, José, Cortes, Claudia, Altclas, Javier, Silvia Kogan, Sanatorio, Spelman, Denis, Athan, Eugene, Harris, Owen, Kennedy, Karina, Tan, Ren, Gordon, David, Papanicolas, Lito, Eisen, Damon, Grigg, Leeanne, Street, Alan, Korman, Tony, Kotsanas, Despina, Dever, Robyn, Jones, Phillip, Konecny, Pam, Lawrence, Richard, Rees, David, Ryan, Suzanne, Feneley, Michael P., Post, Jeffrey, Reinbott, Porl, Gattringer, Rainer, Wiesbauer, Franz, Andrade, Adriana Ribas, de Brito, Ana Cláudia Passos, Guimarães, Armenio Costa, Grinberg, Max, Mansur, Alfredo José, Siciliano, Rinaldo Focaccia, Strabelli, Tania Mara Varejao, Vieira, Marcelo Luiz Campos, de Medeiros Tranchesi, Regina Aparecida, Paiva, Marcelo Goulart, Fortes, Claudio Querido, de Oliveira Ramos, Auristela, Ferraiuoli, Giovanna, Golebiovski, Wilma, Lamas, Cristiane, Santos, Marisa, Weksler, Clara, Karlowsky, James A., Keynan, Yoav, Morris, Andrew M., Rubinstein, Ethan, Jones, Sandra Braun, Garcia, Patricia, Cereceda, M., Fica, Alberto, Mella, Rodrigo Montagna, Barsic, Bruno, Bukovski, Suzana, Krajinovic, Vladimir, Pangercic, Ana, Rudez, Igor, Vincelj, Josip, Freiberger, Tomas, Pol, Jiri, Zaloudikova, Barbora, Ashour, Zainab, Kholy, Amani El, Mishaal, Marwa, Rizk, Hussien, Aissa, Neijla, Alauzet, Corentine, Alla, Francois, Campagnac, Catherine, Doco Lecompte, Thanh, Selton Suty, Christine, Casalta, Jean Paul, Fournier, Pierre Edouard, Habib, Gilbert, Raoult, Didier, Thuny, Franck, Delahaye, Francois, Delahaye, Armelle, Vandenesch, Francois, Donal, Erwan, Donnio, Pierre Yves, Michelet, Christian, Revest, Matthieu, Tattevin, Pierre, Violette, Jérémie, Chevalier, Florent, Jeu, Antoine, Rusinaru, Dan M. D., Sorel, Claire, Tribouilloy, Christophe, Bernard, Yvette, Chirouze, Catherine, Hoen, Bruno, Leroy, Joel, Plesiat, Patrick, Naber, Christoph, Neuerburg, Carl, Mazaheri, Bahram, Athanasia, Sofia, Giannitsioti, Efthymia, Mylona, Elena, Paniara, Olga, Papanicolaou, Konstantinos, Pyros, John, Skoutelis, Athanasios, Sharma, Gautam, Francis, Johnson, Nair, Lathi, Thomas, Vinod, Venugopal, Krishnan, Hannan, Margaret, Hurley, John, Gilon, Dan, Israel, Sarah, Korem, Maya, Strahilevitz, Jacob, Tripodi, Marie Françoise, Casillo, Roberta, Cuccurullo, Susanna, Dialetto, Giovanni, Durante Mangoni, Emanuele, Irene, Mattucci, Ragone, Enrico, Utili, Riccardo, Cecchi, Enrico, De Rosa, Francesco, Imazio, Massimo, Trinchero, Rita, Tebini, Alessandro, Grossi, PAOLO ANTONIO, Lattanzio, Mariangela, Toniolo, Antonio, Goglio, Antonio, Raglio, Annibale, Ravasio, Veronica, Rizzi, Marco, Suter, Fredy, Carosi, Giampiero, Magri, Silvia, Signorini, Liana, Baban, Tania, Kanafani, Zeina, Kanj, Souha S., Sfeir, Jad, Yasmine, Mohamad, Abidin, Imran, Tamin, Syahidah Syed, Martínez, Eduardo Rivera, Nieto, Gabriel Israel Soto, van der Meer, Jan T. M., Chambers, Stephen, Murdoch, David R., Dragulescu, Stefan, Ionac, Adina, Mornos, Cristian, Butkevich, O. M., Chipigina, Natalia, Kirill, Ozerecky, Vadim, Kulichenko, Edathodu, Jameela, Halim, Magid, Lum, Luh Nah, Tan, Ru San, Lejko Zupanc, Tatjana, Logar, Mateja, Mueller Premru, Manica, Commerford, Patrick, Commerford, Anita, Deetlefs, Eduan, Hansa, Cass, Ntsekhe, Mpiko, Almela, Manuel, Armero, Yolanda, Azqueta, Manuel, Castañeda, Ximena, Cervera, Carlos, Falces, Carlos, Garcia de la Maria, Cristina, Fita, Guillermina, Gatell, Jose M., Marco, Francesc, Mestres, Carlos A., Miró, José M., Moreno, Asuncion, Ninot, Salvador, Paré, Carlos, Pericas, Joan, Ramirez, Jose, Rovira, Irene, Sitges, Marta, Anguera, Ignasi, Font, Bernat, Guma, Joan Raimon, Bermejo, Javier, Fernández, Miguel Angel Garcia, Gonzalez Ramallo, Victor, Marín, Mercedes, Muñoz, Patricia, Pedromingo, Miguel, Roda, Jorge, Rodríguez Créixems, Marta, Solis, Jorge, Fernandez Hidalgo, Nuria, Tornos, Pilar, de Alarcón, Arístides, Parra, Ricardo, Alestig, Eric, Johansson, Magnus, Olaison, Lars, Snygg Martin, Ulrika, Pachirat, Orathai, Pachirat, Pimchitra, Pussadhamma, Burabha, Senthong, Vichai, Casey, Anna, Elliott, Tom, Lambert, Peter, Watkin, Richard, Eyton, Christina, Klein, John L., Bradley, Suzanne, Kauffman, Carol, Bedimo, Roger, Crowley, Anna Lisa, Douglas, Pamela, Drew, Laura, Fowler, Vance G., Holland, Thomas, Mudrick, Daniel, Samad, Zaniab, Sexton, Daniel, Stryjewski, Martin, Wang, Andrew, Lerakis, Stamatios, Cantey, Robert, Steed, Lisa, Dickerman, Stuart A., Bonilla, Hector, Dipersio, Joseph, Salstrom, Sara Jane, Baddley, John, Patel, Mukesh, Peterson, Gail, Stancoven, Amy, Afonso, Luis, Kulman, Theresa, Levine, Donald, Rybak, Michael, Cabell, Christopher H., Baloch, Khaula, Dixon, Christy C., Vance G., Fowler J. r., Harding, Tina, Jones Richmond, Marian, Park, Lawrence P., Redick, Thomas, Stafford, Judy, Anstrom, Kevin, Bayer, Arnold S., Karchmer, A. W., Sexton, Daniel J., Cabell, Christopher H, Chu, Vivian, Durack, David T., Eykyn, Susannah, Moreillon, Phillipe, Universitat de Barcelona, University of Otago [Dunedin, Nouvelle-Zélande], Auckland City Hospital, Microbiology Laboratory, Middlemore Hospital, Duke University Medical Center, Clinical and experimental neuroimmunology [IDIBAPS], Institut d'Investigacions Biomèdiques August Pi i Sunyer, Vall d'Hebron University Hospital [Barcelona], Hospital Universitario Gregorio Maranon, Hospital Universitario Gregorio Marañón, Cardiologie, Maria Vittoria Hospital [Turin], Mater Hospitals, University of New South Wales [Sydney] (UNSW), American University of Beirut [Beyrouth] (AUB), Uniformed Services University of the Health Sciences (USUHS), Wellington Hospital Private, Royal North Shore Hospital (RNSH), Russian State Medical University, Durham VA Medical Center, and University of South Carolina [Columbia]

Subjects
Aortic valve, Bacterial Diseases, Genetics and Molecular Biology (all), Valvular Disease, Medizin, Eikenella corrodens, Cardiobacterium, Infection control, Cardiovascular, American-heart-association, Biochemistry, Antimicrobial therapy, Cohort Studies, 0302 clinical medicine, Control d'infeccions, Diagnosis, Odds Ratio, Prevalence, 030212 general & internal medicine, Prospective cohort study, Haemophilus Influenzae, 0303 health sciences, Multidisciplinary, biology, Endocarditis, Medicine (all), Statistics, Congenital Heart Disease, Age Factors, Bacterial, 3. Good health, Management, Stroke, medicine.anatomical_structure, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Treatment Outcome, Infective endocarditis, Cohort, [SDV.IMM]Life Sciences [q-bio]/Immunology, Medicine, Profile, Health-care professionals, Kingella, Cardiobacterium-hominis, Cohort study, Research Article, medicine.medical_specialty, Drugs and Devices, Science, Haemophilus, Referral bias, Statistics, Nonparametric, Medical Devices, 03 medical and health sciences, Internal medicine, Kingella Kingae Infection, medicine, Humans, Nonparametric, Aggregatibacter, Endocarditis, Bacterial, Biochemistry, Genetics and Molecular Biology (all), Agricultural and Biological Sciences (all), Staphylococcus-aureus, Heart Failure, 030306 microbiology, business.industry, Acute Cardiovascular Problems, Bloodstream Infections, medicine.disease, biology.organism_classification, Surgery, Valve endocarditis, Cardiobacterium hominis, business
Abstract

International audience; The HACEK organisms (Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella species) are rare causes of infective endocarditis (IE). The objective of this study is to describe the clinical characteristics and outcomes of patients with HACEK endocarditis (HE) in a large multi-national cohort. Patients hospitalized with definite or possible infective endocarditis by the International Collaboration on Endocarditis Prospective Cohort Study in 64 hospitals from 28 countries were included and characteristics of HE patients compared with IE due to other pathogens. Of 5591 patients enrolled, 77 (1.4%) had HE. HE was associated with a younger age (47 vs. 61 years; p < 0.001), a higher prevalence of immunologic/vascular manifestations (32% vs. 20%; p < 0.008) and stroke (25% vs. 17% p = 0.05) but a lower prevalence of congestive heart failure (15% vs. 30%; p = 0.004), death in-hospital (4% vs. 18%; p = 0.001) or after 1 year follow-up (6% vs. 20%; p = 0.01) than IE due to other pathogens (n = 5514). On multivariable analysis, stroke was associated with mitral valve vegetations (OR 3.60; CI 1.34-9.65; p < 0.01) and younger age (OR 0.62; CI 0.49-0.90; p < 0.01). The overall outcome of HE was excellent with the in-hospital mortality (4%) significantly better than for non-HE (18%; p < 0.001). Prosthetic valve endocarditis was more common in HE (35%) than non-HE (24%). The outcome of prosthetic valve and native valve HE was excellent whether treated medically or with surgery. Current treatment is very successful for the management of both native valve prosthetic valve HE but further studies are needed to determine why HE has a predilection for younger people and to cause stroke. The small number of patients and observational design limit inferences on treatment strategies. Self selection of study sites limits epidemiological inferences.

Published
2013

20. Dysregulation of microRNAs in adrenocortical tumors

Author

Stan B. Sidhu, Nadia Cherradi, Patsy S. Soon, Jean-Jacques Feige, Olivier Chabre, Enzo Lalli, Puneet Singh, Jing Ting Zhao, Department of Surgery, Bankstown Hospital and South Western Sydney Clinical School, University of New South Wales [Sydney] (UNSW), Cancer Genetics Unit, Hormones & Cancer Group, The University of Sydney, Biology of Cancer and Infection, Université Joseph Fourier - Grenoble 1 (UJF), Biologie du Cancer et de l'Infection (BCI ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre Hospitalier Universitaire de Grenoble, CHU Grenoble, Institut de pharmacologie moléculaire et cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Department of Endocrine and Oncology Surgery, Royal North Shore Hospital (RNSH), Université Nice Sophia Antipolis (1965 - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)

Subjects
MESH: Survival Rate, Disease, MESH: Adrenal Cortex Neoplasms, Biology, Bioinformatics, Biochemistry, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Mirna expression, microRNA, Animals, Humans, MESH: Animals, Epigenetics, RNA, Neoplasm, Molecular Biology, Gene, 030304 developmental biology, 0303 health sciences, MESH: Humans, Disease specific survival, MESH: Gene Expression Regulation, Neoplastic, MESH: RNA, Neoplasm, Adrenal Cortex Neoplasms, 3. Good health, Gene Expression Regulation, Neoplastic, Survival Rate, stomatognathic diseases, MicroRNAs, 030220 oncology & carcinogenesis, Risk stratification, MESH: Disease-Free Survival, Adrenocortical Adenoma, Cancer development, MESH: Adrenocortical Adenoma, MESH: MicroRNAs, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; MicroRNAs (miRNAs) are short non-coding RNAs that are involved in the epigenetic regulation of cellular processes. Different malignancies are often associated with the deregulation of specific sets of miRNAs. The prognosis of adrenocortical cancers (ACCs) is very poor as compared to adrenocortical adenomas (ACAs), and even within ACCs there are cases with better disease specific survival. An improved understanding of the pathobiology of this disease will therefore be useful in facilitating better management of ACCs as well as distinguishing high risk versus low risk subgroups. One third of coding genes are regulated by miRNAs and therefore changes in miRNA expression may be associated with cancer development and progression. In this review we summarize the current understanding of miRNAs in adrenocortical tumors, and highlight their potential in differentiating between ACCs and ACAs, risk stratification and prognosis.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results